Novavax COVID-19 vaccine safety data - All participants

Data on this page show the responses of all individuals who received the original formulation Novavax COVID-19 vaccine and completed an AusVaxSafety survey sent on day 3 after vaccination. Note: The original formulation Novavax COVID-19 vaccine is no longer being administered in Australia; therefore, original formulation Novavax COVID-19 vaccine safety data below are no longer updated. AusVaxSafety has retained the display of historical original formulation Novavax COVID-19 vaccine safety data as a reference.

AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.

Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here.

Links to further information on the expected profile for the Novavax COVID-19 vaccine are available below: 

• Australian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on use of COVID-19 vaccine in Australia
• Australian Technical Advisory Group on Immunisation (ATAGI) recommendations on the use of a booster dose of COVID-19 vaccine
• Australian Technical Advisory Group on Immunisation (ATAGI) statement on recommendations on a winter booster dose of COVID-19 vaccine
• Novavax COVID-19 vaccine phase III trial publication  

AusVaxSafety will continue to closely monitor the safety data of all COVID-19 vaccines in use in Australia in conjunction with the TGA.